Dr. Carla Greenbaum, MD
Claim this profileBenaroya Research Institute
Studies Type 1 Diabetes
Studies Insulin Resistance
4 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Carla Greenbaum, MD is currently running
Observational Study
for Type 1 Diabetes
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Recruiting1 award N/A2 criteria
Prevention
for Type 1 Diabetes
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM. Purpose: TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes. The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes.
Recruiting1 award N/A3 criteria
More about Carla Greenbaum, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Carla Greenbaum, MD has experience with
- Screening And Monitoring For Type 1 Diabetes Risk
- NNC0361-0041
- Hydroxychloroquine
- Placebo
Breakdown of trials Carla Greenbaum, MD has run
Type 1 Diabetes
Insulin Resistance
Impaired Glucose Tolerance
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carla Greenbaum, MD specialize in?
Carla Greenbaum, MD focuses on Type 1 Diabetes and Insulin Resistance. In particular, much of their work with Type 1 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Carla Greenbaum, MD currently recruiting for clinical trials?
Yes, Carla Greenbaum, MD is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Carla Greenbaum, MD has studied deeply?
Yes, Carla Greenbaum, MD has studied treatments such as Screening and Monitoring for Type 1 Diabetes Risk, NNC0361-0041, Hydroxychloroquine.
What is the best way to schedule an appointment with Carla Greenbaum, MD?
Apply for one of the trials that Carla Greenbaum, MD is conducting.
What is the office address of Carla Greenbaum, MD?
The office of Carla Greenbaum, MD is located at: Benaroya Research Institute, Seattle, Washington 98101-2795 United States. This is the address for their practice at the Benaroya Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.